Aquestive Therapeutics, Inc. (AQST)
3.515
-0.19
(-5.13%)
USD |
NASDAQ |
Nov 20, 14:22
Aquestive Therapeutics Enterprise Value : 525.15M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 525.15M |
| November 18, 2026 | 534.57M |
| November 17, 2026 | 524.52M |
| November 16, 2026 | 532.06M |
| November 13, 2026 | 550.91M |
| November 12, 2026 | 508.18M |
| November 11, 2026 | 509.44M |
| November 10, 2026 | 501.89M |
| November 09, 2026 | 504.41M |
| November 06, 2026 | 513.21M |
| November 05, 2026 | 519.49M |
| November 04, 2026 | 537.09M |
| November 03, 2026 | 547.14M |
| November 02, 2026 | 533.32M |
| October 30, 2026 | 548.40M |
| October 29, 2026 | 567.25M |
| October 28, 2026 | 591.13M |
| October 27, 2026 | 571.02M |
| October 26, 2026 | 558.45M |
| October 23, 2026 | 562.22M |
| October 22, 2026 | 578.56M |
| October 21, 2026 | 572.28M |
| October 20, 2026 | 568.51M |
| October 19, 2026 | 540.86M |
| October 16, 2026 | 534.57M |
| Date | Value |
|---|---|
| October 15, 2026 | 569.77M |
| October 14, 2026 | 638.89M |
| October 13, 2026 | 646.44M |
| October 12, 2026 | 664.03M |
| October 09, 2026 | 660.26M |
| October 08, 2026 | 657.75M |
| October 07, 2026 | 640.15M |
| October 06, 2026 | 638.89M |
| October 05, 2026 | 633.87M |
| October 02, 2026 | 631.35M |
| October 01, 2026 | 617.53M |
| September 30, 2026 | 641.41M |
| September 29, 2026 | 636.73M |
| September 28, 2026 | 646.78M |
| September 25, 2026 | 637.99M |
| September 24, 2026 | 655.56M |
| September 23, 2026 | 640.50M |
| September 22, 2026 | 671.88M |
| September 21, 2026 | 650.54M |
| September 18, 2026 | 629.20M |
| September 17, 2026 | 635.48M |
| September 16, 2026 | 655.56M |
| September 15, 2026 | 654.31M |
| September 14, 2026 | 663.09M |
| September 11, 2026 | 650.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eton Pharmaceuticals, Inc. | 1.738B |
| Corcept Therapeutics, Inc. | 6.745B |
| ANI Pharmaceuticals, Inc. | 1.754B |
| Veru, Inc. | 12.87M |
| Johnson & Johnson | 670.46B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.50M |
| Revenue (Quarterly) | 7.557M |
| Total Expenses (Quarterly) | 24.05M |
| EPS Diluted (Quarterly) | -0.1314 |
| Gross Profit Margin (Quarterly) | 52.28% |
| Profit Margin (Quarterly) | -218.3% |
| Earnings Yield | -18.24% |
| Normalized Earnings Yield | -16.38 |